歌礼制药(01672.HK)治疗银屑病药物ASC50获美国批准I期新药临床试验

阿斯达克财经
22 May

歌礼制药-B(01672.HK) 公布,其治疗轻中度斑块状银屑病的ASC50的I期新药临床试验申请(IND)已于近期获美国食品药品监督管理局(FDA)批准。
ASC50为歌礼自主研发的口服小分子白细胞介素-17(IL-17)靶向抑制剂,该靶点在银屑病等多种自身免疫及炎症性疾病领域已获充分的生物学验证并具备成熟商业价值。

ASC50的该项I期临床试验为随机、双盲、安慰剂对照的研究,将在美国多个中心开展,预计将于今年第三季度开始在轻中度斑块状银屑病人中给药。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-22 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10